Business
Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD)
Winter Park, Florida--(Newsfile Corp. - May 5, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company based in Winter Park, Florida, dedicated to advancing regenerative therapies for chronic diseases, today announced that its pivotal clinical study on kidney disease has received Institutional Review Board (IRB) approval and has been successfully submitted to ClinicalTrials.gov.Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - May 5, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company based in Winter Park, Florida, dedicated to advancing regenerative therapies for chronic diseases, today announced that its pivotal clinical study on kidney disease has received Institutional Review Board (IRB) approval and has been successfully submitted to ClinicalTrials.gov.","length":395,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":550,"height":481,"url":"https://media.zenfs.com/en/newsfile_64/acc272bf2b461295073a11e8c13c3820"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UwjecaWmIp64Hca071Afrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg0MA--/https://media.zenfs.com/en/newsfile_64/acc272bf2b461295073a11e8c13c3820","width":550,"height":481}},"href":"https://images.newsfilecorp.com/files/10520/295970_ckdstudy.jpg","hrefExternal":true},{"type":"text","content":"Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD)","length":138,"tagName":"p","attribs":{}},{"type":"text","content":"To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/295970_ckdstudy.jpg","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"This milestone marks an important step in Adia Nutrition's ongoing research into new approaches for studying kidney disease. The approved study will focus on evaluating the safety of the company's proprietary AdiaVita stem cell-based approach, which uses stem cells and exosomes derived from umbilical cord blood, in people with moderate to advanced chronic kidney disease (CKD). In addition to safety, the study will track changes in commonly used kidney function and inflammation markers over time to better understand how patients respond during the study period.","length":574,"tagName":"p"},{"type":"text","content":""IRB approval and our submission to ClinicalTrials.gov are important milestones that confirm this study meets established ethical and regulatory standards," said Larry Powalisz, CEO of Adia Nutrition. "Reaching this stage allows us to move forward with participant recruitment and begin the structured process of collecting c...